This is worth knowing as pan-PIM kinase inhibitors are in development as anti-cancer drugs and it has been suggested that PIM inhibitors might be used as a strategy to generate more stem-memory-like CD8 T cells in combination with cancer immunotherapy treatments (Chatterjee et al., 2019; Clements and Warfel, 2022). The gene discussed is CD8A; the disease is cancer.